Case report: Kinetics of human leukocyte antigen receptor HLA-DR during liver injury induced by potassium para-aminobenzoate as assessed for causality using the updated RUCAM
Potassium para-aminobenzoate (POTABA) is used to treat Peyronie’s disease by decreasing fibrosis and plaque size progression. Among potential side effects, drug-induced liver injury (DILI) attributed to POTABA administration has been reported in a few cases and inferred to immune hypersensitivity. I...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-08-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2022.966910/full |
| _version_ | 1828182407735410688 |
|---|---|
| author | Marlene Plüß Désirée Tampe Harald Schwörer Sebastian Christopher Benjamin Bremer Björn Tampe |
| author_facet | Marlene Plüß Désirée Tampe Harald Schwörer Sebastian Christopher Benjamin Bremer Björn Tampe |
| author_sort | Marlene Plüß |
| collection | DOAJ |
| description | Potassium para-aminobenzoate (POTABA) is used to treat Peyronie’s disease by decreasing fibrosis and plaque size progression. Among potential side effects, drug-induced liver injury (DILI) attributed to POTABA administration has been reported in a few cases and inferred to immune hypersensitivity. In the present case, we investigated clinical, biochemical, and serological features as well as searched for non-drug-related causes, and applied the updated Roussel Uclaf Causality Assessment Method (RUCAM) confirming a highly probable causality of POTABA-induced liver injury. Moreover, we here observed specific activated CD3+ T lymphocytes during the acute phase of liver injury by monitoring of human leukocyte antigen receptor (HLA-DR) expression. Furthermore, improvement of biochemical markers of liver injury after POTABA withdrawal was associated with a rapid decline of CD3+ HLA-DR+ immune cells. In contrast, CD14+ monocytes expressing HLA-DR remained stable during recovery from liver injury. These observations implicate a specific involvement of activated T lymphocytes in liver injury mediated by POTABA. Clinicians should be aware of POTABA-induced liver injury, and measurement of activated immune cells by assessment of HLA-DR could provide pathomechanistic insights enabling biomonitoring of recovery from DILI. |
| first_indexed | 2024-04-12T06:17:01Z |
| format | Article |
| id | doaj.art-57ba4c5274df4e4dbaea872597a4b75d |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-04-12T06:17:01Z |
| publishDate | 2022-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-57ba4c5274df4e4dbaea872597a4b75d2022-12-22T03:44:26ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122022-08-011310.3389/fphar.2022.966910966910Case report: Kinetics of human leukocyte antigen receptor HLA-DR during liver injury induced by potassium para-aminobenzoate as assessed for causality using the updated RUCAMMarlene Plüß0Désirée Tampe1Harald Schwörer2Sebastian Christopher Benjamin Bremer3Björn Tampe4Department of Nephrology and Rheumatology, University Medical Center Göttingen, Göttingen, GermanyDepartment of Nephrology and Rheumatology, University Medical Center Göttingen, Göttingen, GermanyDepartment of Gastroenterology, Gastrointestinal Oncology and Endocrinology, University Medical Center Göttingen, Göttingen, GermanyDepartment of Gastroenterology, Gastrointestinal Oncology and Endocrinology, University Medical Center Göttingen, Göttingen, GermanyDepartment of Nephrology and Rheumatology, University Medical Center Göttingen, Göttingen, GermanyPotassium para-aminobenzoate (POTABA) is used to treat Peyronie’s disease by decreasing fibrosis and plaque size progression. Among potential side effects, drug-induced liver injury (DILI) attributed to POTABA administration has been reported in a few cases and inferred to immune hypersensitivity. In the present case, we investigated clinical, biochemical, and serological features as well as searched for non-drug-related causes, and applied the updated Roussel Uclaf Causality Assessment Method (RUCAM) confirming a highly probable causality of POTABA-induced liver injury. Moreover, we here observed specific activated CD3+ T lymphocytes during the acute phase of liver injury by monitoring of human leukocyte antigen receptor (HLA-DR) expression. Furthermore, improvement of biochemical markers of liver injury after POTABA withdrawal was associated with a rapid decline of CD3+ HLA-DR+ immune cells. In contrast, CD14+ monocytes expressing HLA-DR remained stable during recovery from liver injury. These observations implicate a specific involvement of activated T lymphocytes in liver injury mediated by POTABA. Clinicians should be aware of POTABA-induced liver injury, and measurement of activated immune cells by assessment of HLA-DR could provide pathomechanistic insights enabling biomonitoring of recovery from DILI.https://www.frontiersin.org/articles/10.3389/fphar.2022.966910/fullhepatotoxicityacute hepatitisdrug-induced liver injuryRoussel Uclaf causality assessment methodupdated RUCAMpotassium para-aminobenzoate |
| spellingShingle | Marlene Plüß Désirée Tampe Harald Schwörer Sebastian Christopher Benjamin Bremer Björn Tampe Case report: Kinetics of human leukocyte antigen receptor HLA-DR during liver injury induced by potassium para-aminobenzoate as assessed for causality using the updated RUCAM Frontiers in Pharmacology hepatotoxicity acute hepatitis drug-induced liver injury Roussel Uclaf causality assessment method updated RUCAM potassium para-aminobenzoate |
| title | Case report: Kinetics of human leukocyte antigen receptor HLA-DR during liver injury induced by potassium para-aminobenzoate as assessed for causality using the updated RUCAM |
| title_full | Case report: Kinetics of human leukocyte antigen receptor HLA-DR during liver injury induced by potassium para-aminobenzoate as assessed for causality using the updated RUCAM |
| title_fullStr | Case report: Kinetics of human leukocyte antigen receptor HLA-DR during liver injury induced by potassium para-aminobenzoate as assessed for causality using the updated RUCAM |
| title_full_unstemmed | Case report: Kinetics of human leukocyte antigen receptor HLA-DR during liver injury induced by potassium para-aminobenzoate as assessed for causality using the updated RUCAM |
| title_short | Case report: Kinetics of human leukocyte antigen receptor HLA-DR during liver injury induced by potassium para-aminobenzoate as assessed for causality using the updated RUCAM |
| title_sort | case report kinetics of human leukocyte antigen receptor hla dr during liver injury induced by potassium para aminobenzoate as assessed for causality using the updated rucam |
| topic | hepatotoxicity acute hepatitis drug-induced liver injury Roussel Uclaf causality assessment method updated RUCAM potassium para-aminobenzoate |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2022.966910/full |
| work_keys_str_mv | AT marlenepluß casereportkineticsofhumanleukocyteantigenreceptorhladrduringliverinjuryinducedbypotassiumparaaminobenzoateasassessedforcausalityusingtheupdatedrucam AT desireetampe casereportkineticsofhumanleukocyteantigenreceptorhladrduringliverinjuryinducedbypotassiumparaaminobenzoateasassessedforcausalityusingtheupdatedrucam AT haraldschworer casereportkineticsofhumanleukocyteantigenreceptorhladrduringliverinjuryinducedbypotassiumparaaminobenzoateasassessedforcausalityusingtheupdatedrucam AT sebastianchristopherbenjaminbremer casereportkineticsofhumanleukocyteantigenreceptorhladrduringliverinjuryinducedbypotassiumparaaminobenzoateasassessedforcausalityusingtheupdatedrucam AT bjorntampe casereportkineticsofhumanleukocyteantigenreceptorhladrduringliverinjuryinducedbypotassiumparaaminobenzoateasassessedforcausalityusingtheupdatedrucam |